<p>Shanghai Haohai Biological Technology Co. Ltd. has provided a supplemental update regarding its acquisition of equity interest in Jiangxi Ruiji Bio-Engineering Technology Co., Ltd. The update includes further details on the valuation of the target company, noting that the RMB4.53 per share price was determined through arm’s length negotiations. The company also clarified that the ultimate beneficial owner of the target company is controlled by Shanghai Xinji Enterprise Management Partnership, holding approximately 24.61% interest, and Mr. Lou Guoliang, who holds around 8.15%. The acquisition is expected to strengthen Shanghai Haohai’s distribution rights and foundation in related business areas, leveraging Jiangxi Ruiji’s robust pipeline in biomedical materials. All other terms of the transaction remain unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Haohai Biological Technology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260107-11983506), on January 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Shanghai Haohai Updates Valuation Details in Jiangxi Ruiji Bio-Engineering Acquisition